STOCK TITAN

Rocket Pharmaceuticals (RCKT) director Southwell awarded RSUs and 64,860-share option

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ROCKET PHARMACEUTALS, INC. director David P. Southwell reported equity awards, not open-market trades. He received 22,862 restricted stock units (RSUs) that convert one-for-one into common stock and will vest in full on June 18, 2027. He was also granted a stock option for 64,860 shares of common stock at an exercise price of $3.35 per share, which becomes fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following these awards, he directly owns 54,522 shares of common stock and indirectly holds 113,124 shares through The David P. Southwell Irrevocable Trust dated April 14, 2024.

Positive

  • None.

Negative

  • None.
Insider SOUTHWELL DAVID P
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 64,860 $0.00 --
Grant/Award Common Stock 22,862 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 64,860 shares (Direct, null); Common Stock — 54,522 shares (Direct, null); Common Stock — 113,124 shares (Indirect, By The David P. Southwell Irrevocable Trust Dtd 04/14/2024)
Footnotes (1)
  1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
RSU grant size 22,862 RSUs Restricted stock units vesting June 18, 2027
Option shares granted 64,860 shares Stock option for Rocket Pharmaceuticals common stock
Option exercise price $3.35 per share Strike price for 64,860-share option
Option expiration June 18, 2036 Expiration date of granted stock option
RSU vesting date June 18, 2027 Full vesting date for 22,862 RSUs
Direct shares after awards 54,522 shares Direct Rocket Pharmaceuticals holdings post-transaction
Indirect trust holdings 113,124 shares Held by The David P. Southwell Irrevocable Trust
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 64,860 underlying shares of Common Stock."
exercise price financial
"conversion_or_exercise_price": "3.3500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
irrevocable trust financial
"By The David P. Southwell Irrevocable Trust Dtd 04/14/2024"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
vest financial
"The RSUs will vest in full on June 18, 2027."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SOUTHWELL DAVID P

(Last)(First)(Middle)
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE

(Street)
CRANBURY NEW JERSEY 08512

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)06/18/2026A22,862A$0(1)54,522D
Common Stock113,124IBy The David P. Southwell Irrevocable Trust Dtd 04/14/2024
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.3506/18/2026A64,860 (2)06/18/2036Common Stock64,860$064,860D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
/s/ Martin Wilson, as attorney-in-fact for David Southwell07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did RCKT director David P. Southwell report?

David P. Southwell reported equity awards in Rocket Pharmaceuticals stock, not market trades. He received 22,862 RSUs and a stock option for 64,860 shares, both vesting in 2027 as part of his director compensation.

How many Rocket Pharmaceuticals (RCKT) RSUs were granted to David P. Southwell?

He received 22,862 restricted stock units that convert to Rocket Pharmaceuticals common stock on a one-for-one basis. These RSUs vest in full on June 18, 2027, aligning compensation with longer-term company performance and continued service.

What are the terms of David P. Southwell’s new stock option in RCKT?

He was granted a stock option for 64,860 shares of Rocket Pharmaceuticals common stock at an exercise price of $3.35 per share. The option fully vests on June 18, 2027 and expires on June 18, 2036, supporting long-term alignment.

Did David P. Southwell buy or sell Rocket Pharmaceuticals (RCKT) shares on the market?

The filing shows compensation-related awards, not open-market buying or selling. Reported transactions include RSU and stock option grants with a $0.00 transaction price, indicating they are part of his director compensation rather than discretionary trades.

What is David P. Southwell’s Rocket Pharmaceuticals share ownership after these awards?

After the reported awards, he holds 54,522 Rocket Pharmaceuticals common shares directly. He also has an indirect interest in 113,124 shares held by The David P. Southwell Irrevocable Trust dated April 14, 2024, as disclosed in the filing.

When do David P. Southwell’s Rocket Pharmaceuticals RSUs and options vest?

Both equity awards have a single future vesting date. The 22,862 RSUs vest in full on June 18, 2027, and the option for 64,860 shares also becomes fully vested and exercisable on that same June 18, 2027 date.